Evidence map›Paper›PMID 20204358›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2010

(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Gerard Moulin-Romsee, Elif Hindié, Xavier Cuenca, Pauline Brice, Didier Decaudin, Myriam Bénamor, Josette Brière, Marcela Anitei, Jean-Emmanuel Filmont, David Sibon and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Guideline
  2. Trial
  3. How I treat advanced Hodgkin lymphoma - a global view.British journal of haematology · 2020
    Review
  4. Review
  5. (2S,4R)-4-[Molecular imaging and biology · 2019
    Article
  6. Article
  7. Article
  8. Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.European journal of nuclear medicine and molecular imaging · 2017
    Article
  9. European journal of nuclear medicine and molecular imaging · 2017
    Article
  10. Efficacy ofMolecular imaging and radionuclide therapy · 2017
    Article
  11. The role of FDG-PET in Hodgkin lymphoma.Contemporary oncology (Poznan, Poland) · 2017
    Review
  12. Mechanisms underlying the association between obesity and Hodgkin lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.European journal of nuclear medicine and molecular imaging · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gerard Moulin-RomseeService de Médicine Nucléaire, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris 7, 1, avenue Claude Vellefaux, 75475, Paris cedex 10, France.
Elif Hindié
Xavier Cuenca
Pauline Brice
Didier Decaudin
Myriam Bénamor
Josette Brière
Marcela Anitei
Jean-Emmanuel Filmont
David Sibon
Eric de Kerviler
Jean-Luc Moretti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAccurate staging of Hodgkin's lymphoma (HL) is necessary in selecting appropriate treatment. Bone marrow trephine biopsy (BMB) is the standard procedure for depicting bone marrow involvement. BMB is invasive and explores a limited part of the bone marrow. (18)F-FDG PET/CT is now widely used for assessing response to therapy in HL and a baseline study is obtained to improve accuracy. The aim of this retrospective analysis was to assess whether routine BMB remains necessary with concomitant (18)F-FDG PET/CT.

methodsData from 83 patients (newly diagnosed HL) were reviewed. All patients had received contrast-enhanced CT, BMB and (18)F-FDG PET/CT. Results of BMB were not available at the time of (18)F-FDG PET/CT imaging.

resultsSeven patients had lymphomatous involvement on BMB. Four patients had bone involvement on conventional CT (two with negative BMB). All patients with bone marrow and/or bone lesions at conventional staging were also diagnosed on (18)F-FDG PET/CT scan. PET/CT depicted FDG-avid bone/bone marrow foci in nine additional patients. Four of them had only one or two foci, while the other had multiple foci. However, the iliac crest, site of the BMB, was not involved on (18)F-FDG PET/CT. Osteolytic/sclerotic lesions matching FDG-avid foci were visible on the CT part of PET/CT in three patients. MRI ordered in three other patients suggested bone marrow involvement. Interim and/or end-therapy (18)F-FDG PET/CT documented response of FDG-avid bone/bone marrow foci to chemotherapy in every patient.

conclusion(18)F-FDG PET/CT highly improves sensitivity for diagnosis of bone/bone marrow lesions in HL compared to conventional staging.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyTomography, X-Ray ComputedAdolescentAdultAgedAged, 80 and overBone and BonesBone MarrowChildFemaleHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingFluorodeoxyglucose F18

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.